06.22.26 -- CDMO Selection: Start With The Relationship, Not The RFP

The next era of clinical trials will be defined by global expansion across the Asia-Pacific region, rapid and cost-effective pathways to regulatory approval, and reliable, patient-centric leadership.

This collaboration demonstrates how a partnership-driven approach, combined with technical expertise, can deliver scalable, efficient, and reliable manufacturing solutions that support successful global commercialization.

A strategic framework should outline these ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.

See how integrating in-house plasmid manufacturing and expanded commercialization development helps reduce overall costs while driving significant advancements in gene therapy manufacturing.

Understanding these synergies and their impact on efficiency, safety, and cost-effectiveness is essential for stakeholders navigating the complexities of CGT development and production.

To manufacture your rare disease therapy cost effectively, partner with an experienced CDMO from the outset. The right partner will offer development, manufacturing, quality, and regulatory expertise.

Watch Thomas (TJ) Beadnell share expert insights on developing robust live cell assays for global clinical trials, including best practices for assay logistics, antigen stability, and sample integrity.